TY - JOUR
T1 - Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg
T2 - An Analysis of National Healthcare Insurance Data
AU - Schmitz, Susanne
AU - Vaillant, Michel
AU - Renoux, Christell
AU - Konsbruck, Robert L.
AU - Hertz, Pierre
AU - Perquin, Magali
AU - Pavelka, Lukas
AU - Krüger, Rejko
AU - Huiart, Laetitia
N1 - Funding Information:
This study received funding from the Fonds National de Recherche (FNR) Luxembourg within the context of the National Centre for Excellence in Research on Parkinson’s disease (NCER-PD) and within the PEARL Excellence Programme (FNR/P13/6682797) to RK.
Funding Information:
Susanne Schmitz received funding from the NCER-PD to conduct the work presented in this article. Christel Renoux is a recipient of a Chercheur-Boursier Salary Award from the Fonds de recherche du Québec – Santé. Rejko Krüger serves as an Editorial Board Member of the European Journal of Clinical Investigation, the Journal of Parkinsonism and Related Disorders, and the Journal of Neural Transmission, and has received research grants from Fonds National de Recherche de Luxembourg (FNR) as Coordinator of the NCER-PD and Coordinator of the Study on COvid-19 National survey for assessing VIral spread by Non-affected CarriErs (CON-VINCE), as well as speaker’s honoraria and/or travel grants from Abbvie, Zambonm and Medtronic. He also participated as Principal Investigator (PI) or site PI for industry-sponsored clinical trials without receiving honoraria. Robert L. Konsbruck, Pierre Hertz, Magali Perquin, Lukas Pavelka, Michel Vaillant, and Laetitia Huiart have no conflicts of interest to declare.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/5
Y1 - 2022/5
N2 - Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with an increasing prevalence worldwide. Estimates of the economic burden associated with PD vary widely across existing studies due to differences in setting and study design. The prevalence and cost of care for PD in Luxembourg are currently unknown. Objective: The aims of this study were to estimate (1) the prevalence of PD in Luxembourg and (2) the cost of care for PD to the national healthcare insurance based on routinely collected healthcare data. Methods: This analysis was based on individual patient-level data collected by the national healthcare insurance in Luxembourg during 2007–2017, which covers over 95% of the resident population. People with PD were identified based on drug reimbursement profiles. Cost of care was estimated according to a comparative analysis of the healthcare resources consumed by people with PD compared with an age- and sex-matched control group. Results: We determined a PD prevalence of 928 per 100,000 individuals aged 50 years and older in 2016, higher in men (1032 per 100,000) than in women (831 per 100,000). The total mean cost of care for PD was estimated at €22,673 per patient per year in 2016, with the highest costs being associated with long-term care (69%). Conclusion: This was the first attempt to estimate the prevalence and cost of care of PD in Luxembourg. The work demonstrated the usefulness of routinely collected data in Luxembourg for such analyses. Our study confirms the significant burden of PD to the healthcare system, especially on long-term care.
AB - Background: Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with an increasing prevalence worldwide. Estimates of the economic burden associated with PD vary widely across existing studies due to differences in setting and study design. The prevalence and cost of care for PD in Luxembourg are currently unknown. Objective: The aims of this study were to estimate (1) the prevalence of PD in Luxembourg and (2) the cost of care for PD to the national healthcare insurance based on routinely collected healthcare data. Methods: This analysis was based on individual patient-level data collected by the national healthcare insurance in Luxembourg during 2007–2017, which covers over 95% of the resident population. People with PD were identified based on drug reimbursement profiles. Cost of care was estimated according to a comparative analysis of the healthcare resources consumed by people with PD compared with an age- and sex-matched control group. Results: We determined a PD prevalence of 928 per 100,000 individuals aged 50 years and older in 2016, higher in men (1032 per 100,000) than in women (831 per 100,000). The total mean cost of care for PD was estimated at €22,673 per patient per year in 2016, with the highest costs being associated with long-term care (69%). Conclusion: This was the first attempt to estimate the prevalence and cost of care of PD in Luxembourg. The work demonstrated the usefulness of routinely collected data in Luxembourg for such analyses. Our study confirms the significant burden of PD to the healthcare system, especially on long-term care.
UR - http://www.scopus.com/inward/record.url?scp=85123100046&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/35034346
U2 - 10.1007/s41669-021-00321-3
DO - 10.1007/s41669-021-00321-3
M3 - Article
C2 - 35034346
AN - SCOPUS:85123100046
SN - 2509-4262
VL - 6
SP - 405
EP - 414
JO - PharmacoEconomics - Open
JF - PharmacoEconomics - Open
IS - 3
ER -